Protein kinase C inhibitors: A patent review (2008-2009)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 10, 2013, Pages 1297-1315

  Sobhia, M Elizabeth ^a   Grewal, Baljinder K ^a   Ml, Stanly Paul ^a   Patel, Jigneshkumar ^a   Kaur, Amandeep ^a   Haokip, Thongtinlal ^a   Kokkula, Alekhya ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

ATP binding site inhibitors; Cancer; Diabetes; Patents; PKCs

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; 7 HYDROXYSTAUROSPORINE; APRINOCARSEN; BISINDOLYLMALEIMIDE; IMATINIB; LESTAURTINIB; LY 317644; LY 326449; MIDOSTAURIN; OLIGONUCLEOTIDE; PEPTIDE; PLACEBO; PROTEIN KINASE C INHIBITOR; PYRIDINE; PYRIMIDINE; PYRROLINE DERIVATIVE; RUBOXISTAURIN; STAUROSPORINE; UNCLASSIFIED DRUG;

ALLOSTERISM; ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; APOPTOSIS; ASTHMA; AUTOIMMUNE DISEASE; BINDING SITE; CALCIUM BINDING; CANCER THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CROHN DISEASE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENZYME ACTIVATION; EYE DISEASE; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; HUMAN; HYPERSENSITIVITY; IN VITRO STUDY; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS; MYOPATHY; NEOVASCULARIZATION (PATHOLOGY); NEUROPATHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; ISOENZYMES; PATENTS AS TOPIC; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS;

EID: 84884539535     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.805205     Document Type: Review

References (72)

1. Newton AC. Protein kinase C. Structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001;101:2353-64 (Pubitemid 35373023)
2. Newton AC. Protein kinase C family. Enc Biol Chem 2004;3:523-6
3. Katz EZ, Glazer RI. Phospholipid and Ca2+-dependent protein kinase activity and protein phosphorylation patterns in the differentiation of human promyelocytic leukemia cell line HL-60. Cancer Res 1985;45:5159-64 (Pubitemid 16236207)
4. Mumby MC, Walter G. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth.Physiol Rev 1993;73:673-99 (Pubitemid 24004649)
5. Inoue M, Kishimoto A, Takai Y, Nishizuka Y. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J Biol Chem 1977;252:7610-16 (Pubitemid 8227337)
6. Marquez VE, Blumberg PM. Synthetic diacylglycerols (DAG) and DAG-Lactones as activators of protein kinase C (PKC). Acc Chem Res 2003;36:434-43
7. Rui L, Archer SF, Argetsinger LS, et al. Platelet-derived growth factor and lysophosphatidic acid inhibit growth hormone binding and signaling via a protein kinase C-dependent pathway. J Biol Chem 2000;275:2885-92 (Pubitemid 30082063)
8. Goel G, Makkar HPS, Francis G, Becker K. Phorbol esters: structure, biological activity, and toxicity in animals. Int J Toxicol 2007;26:279-88 (Pubitemid 47174587)
9. Sansbury M, Johnson EW, Qi C, et al. Effects of protein kinase C activators on phorbol ester-sensitive and -resistant EL4 thymoma cells heather. Carcinogenesis 1997;18:1817-24 (Pubitemid 28134690)
10. Fry DW, Bedford DC, Harvey PH, et al. Cell cycle and biochemical effects of PD 0183812- a potent inhibitor of the cyclin D-dependent kinases cdk4 and cdk6. J Biol Chem 2001;276:16617-23
11. Salles B, Calsou P, Frit P, Muller C. The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol Biol 2006;54:185-93 (Pubitemid 43815658)
12. Hulver MW, Dohm GL. The molecular mechanism linking muscle fat accumulation to insulin resistance. Camb Univ Press 2004;63:375-80 (Pubitemid 38787493)
13. Sobhia ME, Grewal BK, Bhat J, et al. Protein kinase C bII in diabetic complications: survey of structural, biological and computational studies. Expert Opin Ther Targets 2012;16:325-44
14. Newton AC. Regulation of ABC kinases by phosphorylation: protein kinase C as paradigm. Biochem J 2003;370:361-71 (Pubitemid 36315124)
15. Newton AC. The C1 and C2 domains of protein kinase C are independent membrane targeting modules, with specificity for phosphatidylserine conferred by the C domain. Biochemistry 2000;39:11360-9
16. William CW, Wasiuddin AK, Istvan M, et al. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol 1992;117:121-33
17. Harris W, Wilkinson SE, Nixon JS. Recent developments in protein kinase C inhibitors. Expert Opin Ther Patents;7:63-8
18. Shiying L, Yuyang J, Jian C, et al. Inhibitors of protein kinase C. Chin Sci Bull 2005;50:1293-304
19. Lucilia S, Paula F, Eugenia P, Jorge G. Isoform-selectivity of PKC inhibitors acting at the regulatory and catalytic domain of mammalian PKC-A, -bI,-d, -h and -z. J Enzyme Inhib Med Chem 2003;18:475-83
20. Davis PD, Hill CH, Lawton G, et al. Inhibitors of protein kinase C. 1. 2, 3-bisarylmaleimides. J Med Chem 1992;35:177-84
21. Li PF, Maasch C, Haller H, et al. Requirement for protein kinase C in reactive oxygen species-induced apoptosis of vascular smooth muscle cells. Circulation 1999;100:967-73 (Pubitemid 29407178)
22. Dunai ZA, Imre G, Barna G, et al. Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells. PLoS One 2012;7:1-14
23. Wagner J, Von MP, Sedrani RJ, et al. Discovery of 3-(1H-indol-3-yl)-4-[2- (4- methylpiperazin-1-yl)quinazolin-4-yl] pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. Med Chem 2009;52:6193-6
24. Vignot S, Soria JC, Spano JP. Protein kinases C: a new cytoplasmic target. Cancer 2008;95:683-9
25. Wang W, Song N, Zhang H. 6-Hydroxydopamine upregulates iron regulatory protein 1 by activating certain protein kinase C isoforms in the dopaminergic MES23.5 cell line. Int J Biochem Cell Biol 2012;44:1987-92
26. Kawamoto T, Akisue T, Kishimoto K, et al. Inhibition of PKC alpha activation in human bone and soft tissue sarcoma cells by the selective PKC inhibitor PKC412. Anticancer Res 2008;28:825-32 (Pubitemid 351578926)
27. Takahashi I, Asano K, Kawamoto I, et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I. creening, producing organism and fermentation. J Antibiot 1989;42:564-70 (Pubitemid 19119096)
28. Wolf M, Baggiolini M. The protein kinase inhibitor staurosporine, like phorbol esters, induces the association of protein kinase C with membranes. Biochem Biophys Res Commun 1988;154:1273-9
29. Connelly KA, Kelly DJ, Zhang Y, et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009;2:129-37
30. Gschwendt M, Mu?ller HJ, Kielbassa K, et al. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 1994;199:93-8 (Pubitemid 24179919)
31. Fabbro D, Ruetz S, Bodis S, et al. PKC412-A protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28 (Pubitemid 30364896)
32. Jasinski P, Zwolak P, Terai K, et al. PKC-Alpha inhibitor MT477 slows tumor growth with minimal toxicity inin vivo model of non-Ras-mutated cancer via induction of apoptosis. Invest New Drugs 2011;29:33-40
33. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001;10:2117-40 (Pubitemid 34000377)
34. Shen GX. Selective protein kinase C inhibitors and their applications. Curr Drug Targets Cardiovasc Haematol Disord 2003;3:301-7 (Pubitemid 37540861)
35. Bishop WR, Petrin J, Wang L, et al. Inhibition of protein kinase C by the tyrosine kinase inhibitor erbstatin. Biochem Pharmacol 1990;40:2129-35 (Pubitemid 20346466)
36. Willey CD, Xiao D, Tu T, et al. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys 2010;77:1518-26
37. Keenan C, Goode N, Pears C. Isoform specificity of activators and inhibitors of protein kinase C gamma and delta. FEBS Lett 1997;415:101-8 (Pubitemid 27402058)
38. Gopalakrishna R, Chen ZH, Gundimeda U. Irreversible oxidative inactivation of protein kinase C by photosensitive inhibitor calphostin C. FEBS Lett 1992;314:149-54
39. Yang EB, Zhang K, Cheng LY, et al. Butein, a specific protein tyrosine kinase inhibitor. Biochem Biophys Res Commun 1998;245:435-8 (Pubitemid 28418520)
40. Kortmansky J, Schwartz GK. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol 2010;33:121-4
41. Kortmansky J, Schwartz GK. Bryostatin- 1: a novel PKC inhibitor in clinical development. Cancer Invest 2003;21:924-36 (Pubitemid 38055989)
42. Tatsuda Y, Iguchi K, Usui S, et al. Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells. Eur J Pharmacol 2010;627:348-53
43. McGill JB, King GL, Berg PH, et al. Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert Opin Drug Saf 2006;5:835-45 (Pubitemid 44669498)
44. Shen GX. Selective protein kinase C inhibitors and their applications. Curr Drug Targets 2003;3:301-7 (Pubitemid 37540861)
45. Kamran G, Arian L, John JO. Selectivity and therapeutic inhibition of kinases: to be or not tobe? Nat Immunol 2009;10:356-60
46. Charles LS. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010
47. Novartis Pharma GMBH. Use of PKC inhibitors in diabetic complications. W0200081000484A1; 2008
48. Novartis AG and Novartis Pharma GmbH. Use of PKC inhibitors in particular indolylmaleimide derivatives in ocular diseases. WO2008024734A2; 2008
49. Boehringer Ingelheim International GmbH. Pyridine derivatives useful as inhibitors of PKC-theta. US7468382B2; 2008
50. Novartis AG. Indolylmaleimide derivatives as PKC inhibitors. US20080242675A1; 2008
51. The Board of Trustees of the Leland Stanford Junior University. Peptide inhibitors of protein kinase C. US7393835 B2; 2008
52. Pfizer, Inc. 3-Amino-pyrrolo [3, 4-C] pyrazole- 5 (1H, 4H, 6H) carbaldehyde derivatives as PKC inhibitors. WO2008096260; 2008
53. Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pyrimidine derivatives useful as inhibitors of PKC-theta. US7,550,473B2; 2009
54. Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta. US7601714B2; 2009
55. Janssen Pharmaceutica N.V. (BE). Substituted Pyrroline Kinase Inhibitors. US7488826B2; 2009
56. Novartis Corporate Intellectual Property One Health Plaza. Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one jak3 kinase inhibitor for treating autoimmune disorders. US10062301A1; 2009
57. Novartis Corporate Intellectual Property One Health Plaza. Use of midostaurin for treating related gastrointestinal stromal tumors. US 20090075972 A1; 2009
58. Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors. WO2009012421A1; 2009
59. Saliwanchik lloyd & Saliwanchik. Protein kinase c as a target for the treatment of respiratory syncytial virus. US10226423A1; 2009
60. Eder JP, Garcia CR, Clark JW, et al. A phase I trial of daily oral 4'- N - benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs 2004;22:139-50 (Pubitemid 38270469)
61. Cynthia XM, Matthew JC, Gina RP, et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 2013;137:483-92
62. Paula MF, Kerry JW, Ronald CC, et al. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 2011;67:1225-37
63. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001;19:1485-92 (Pubitemid 32202557)
64. Monnerat C, Henriksson R, Le Chevalier T, et al. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 2004;15:316-23 (Pubitemid 38262634)
65. Martiny-Baron G, Kazanietz MG, Mischak H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole G€o 6976. J Biol Chem 1993;268:9194-7 (Pubitemid 23145960)
66. Youn JS, Bok KO, Kang HK, et al. Protein kinase Ca/b inhibitor G€o6976 promotes PC12 cell adhesion and spreading through membrane recruitment and activation of protein kinase Cd. Exp Cell Res 2013;319:153-60
67. Gekeler V, Boer R, Uberall F, et al. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF109203X on P-glycoprotein- mediated multidrug resistance. Br J Cancer 1996;74:897-905 (Pubitemid 26319322)
68. Wilkinson SE, Parker PJ, Nixon JS. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J 1993;294:335-7 (Pubitemid 23268828)
69. Aiello LP, Vignati L, Sheetz MJ, et al. Oral protein kinase c b inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the protein kinase C b inhibitor-diabetic retinopathy study and the protein kinase C b inhibitor-diabetic retinopathy study 2. Retina 2011;10:2084-94
70. Luis PA, Jean YD, Piotr K, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-Alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006;24:1428-34
71. Miguel AV, Paul R, Jose AF, et al. A Phase I/II study of LY900003, an antisense inhibitor of protein kinase Ca,in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10:6086-93
72. Cripps MC, Figueredo AT, Oza AM, et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res 2002;8:2188-92 (Pubitemid 34753589)